Docteur Julia HEITZ

Lieu de consultation

• HOPITAL LE BOCAGE CHRU DIJON

  1 Boulevard JEANNE D ARC, 21079 Dijon

  ☎ 0380293031Hospitalier🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase

  Gynecologic oncology · 2016

  📚 180 citations🎯 RCR 6.33Top 5% NIH
• 2

  Bevacizumab in the treatment of ovarian cancer

  Advances in therapy · 2012

  📚 31 citations
• 3

  Differences in the receptor status between primary and recurrent breast cancer--the frequency of and the reasons for discordance

  Oncology · 2013

  📚 22 citations

  Lire l'abstract Crossref ↓

  <b><i>Objective:</i></b> Receptor discordances between primary and recurrent breast cancer have been described for years, but only a few analyses have elucidated the factors that influence receptor changes. <b><i>Methods:</i></b> Explorative analyses of prospective data from a breast cancer database of a tertiary breast cancer unit. <b><i>Results:</i></b> Recurrent tumours that had expressed oestrogen (ER) and progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2) as primary tumours were negative for the respective receptor in 22.8, 41.4 and 40.8% of cases. ER, PR and HER2 expression was found in 19.8, 16.7 and 11.5% of recurrent tumours, although no expression had been observed in primary tumours. Receptor discordances in recurrent disease leading to different therapeutic approaches were noted in 126 of 411 patients (30.7%). In patients with tumours expressing primary ER and HER2, independent factors associated with discordance were endocrine therapy and treatment with trastuzumab. <b><i>Conclusion:</i></b> High rates of receptor discordance were found. The impact of factors that influence receptor changes is small so that no subgroup of patients with recurrent breast cancer should be excluded from biopsy. Whenever possible, a biopsy should be taken to confirm the diagnosis of a possible relapse as well as the receptor status of patients with breast cancer.

Publications scientifiques (4) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• Combinations of terrain positions and morphologies for retrogressive thaw slumps of different study areas across Siberia

  Image2025Zenodo

  Retrogressive thaw slumps (RTS) from five different study areas in Siberia were classified according to their terrain position and morphology. The methodology is described in the bachelor thesis of Julia Heitz, topic: Va

• Combinations of terrain positions and morphologies for retrogressive thaw slumps of different study areas across Siberia

  Image2025Zenodo

  Retrogressive thaw slumps (RTS) from five different study areas in Siberia were classified according to their terrain position and morphology. The methodology is described in the bachelor thesis of Julia Heitz, topic: Va

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche